Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy

There is an enhanced immune response in patients with breast cancer after the use of chemotherapy. The objective of this study was therefore to investigate alterations in the number of peripheral lymphocytes in patients with breast cancer after neoadjuvant chemotherapy (NC) and the relationship with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tumori 2000-09, Vol.86 (5), p.403-407
Hauptverfasser: Murta, E F, de Andrade, J M, Falcão, R P, Bighetti, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 407
container_issue 5
container_start_page 403
container_title Tumori
container_volume 86
creator Murta, E F
de Andrade, J M
Falcão, R P
Bighetti, S
description There is an enhanced immune response in patients with breast cancer after the use of chemotherapy. The objective of this study was therefore to investigate alterations in the number of peripheral lymphocytes in patients with breast cancer after neoadjuvant chemotherapy (NC) and the relationship with prognosis. Thirty women were analyzed. Their UICC staging was IIb (only T3N0 included) and III (N3 not included). Sample analysis was performed using flow cytometry before the first cycle and 18 to 21 days after the last cycle of NC. The lymphocyte subsets studied were: T (CD3, CD4, CD8), B (CD19, CD23), natural killer (NK) (CD56, CD16), and interleukin-2 (CD25). CD3, CD56, CD8, and CD16 lymphocytes were analyzed with double marking. After x = 3.8 +/- 1.3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC), 16 patients showed a complete or partial response (group 1). After three cycles 14 showed no response or tumor progression (group 2). A control group of healthy women was used for pretreatment analysis. Before NC there was a significant increase in B lymphocytes and NK cells in comparison to the control group. After NC there was a significant percentage increase in CD3, CD4, CD8, CD25 and CD3+CD56+ cells and a decrease in CD19, CD23, CD56, CD16 and CD16+CD8+ cells. There was a significant fall in the absolute number of CD4, CD19, CD23, CD56, CD16 and CD16+CD8+ lymphocytes and an increase in CD3+CD56+ lymphocytes. Before NC the ratio CD4/CD8 in group 1 was 2.25 +/- 0.5 and in group 2 it was 1.79 +/- 0.5 (P
doi_str_mv 10.1177/030089160008600507
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72495293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72495293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-c817c1798f3973c222b3880e4ca373ba524a3227f53f922068671581c7d263503</originalsourceid><addsrcrecordid>eNplkEtPxCAUhYnROOPoH3BhWLmrwqUtsDQTX8kkbnTdUEptJ22pQDX999LMJC7c3Ad85wQOQteU3FHK-T1hhAhJcxJbLBnhJ2gNhIkEMpCnaL0AyUKs0IX3e0JSAnl-jlaUUkYyTtboczf3Y2P1HAz2UznacepUaO3gcTvgMY5mCB7_tKHBqvpWgzYVLp1RPmC9bG6R9W0I8TxYPBirqv0UwXjfmN6Gxjg1zpforFadN1fHvkEfT4_v25dk9_b8un3YJRqkDIkWlGvKpaiZ5EwDQMmEICbVinFWqgxSxQB4nbFaApBc5JxmgmpeQc4ywjbo9uA7Ovs1GR-KvvXadJ2KL5t8wSGVMRwWQTiA2lnvnamL0bW9cnNBSbHEW_yPN4puju7xz6b6kxzzZL-DW3Ws</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72495293</pqid></control><display><type>article</type><title>Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Murta, E F ; de Andrade, J M ; Falcão, R P ; Bighetti, S</creator><creatorcontrib>Murta, E F ; de Andrade, J M ; Falcão, R P ; Bighetti, S</creatorcontrib><description>There is an enhanced immune response in patients with breast cancer after the use of chemotherapy. The objective of this study was therefore to investigate alterations in the number of peripheral lymphocytes in patients with breast cancer after neoadjuvant chemotherapy (NC) and the relationship with prognosis. Thirty women were analyzed. Their UICC staging was IIb (only T3N0 included) and III (N3 not included). Sample analysis was performed using flow cytometry before the first cycle and 18 to 21 days after the last cycle of NC. The lymphocyte subsets studied were: T (CD3, CD4, CD8), B (CD19, CD23), natural killer (NK) (CD56, CD16), and interleukin-2 (CD25). CD3, CD56, CD8, and CD16 lymphocytes were analyzed with double marking. After x = 3.8 +/- 1.3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC), 16 patients showed a complete or partial response (group 1). After three cycles 14 showed no response or tumor progression (group 2). A control group of healthy women was used for pretreatment analysis. Before NC there was a significant increase in B lymphocytes and NK cells in comparison to the control group. After NC there was a significant percentage increase in CD3, CD4, CD8, CD25 and CD3+CD56+ cells and a decrease in CD19, CD23, CD56, CD16 and CD16+CD8+ cells. There was a significant fall in the absolute number of CD4, CD19, CD23, CD56, CD16 and CD16+CD8+ lymphocytes and an increase in CD3+CD56+ lymphocytes. Before NC the ratio CD4/CD8 in group 1 was 2.25 +/- 0.5 and in group 2 it was 1.79 +/- 0.5 (P &lt;0.05). Patients with advanced breast cancer showed increases in B and NK lymphocytes. Neoadjuvant chemotherapy (FEC) caused an increase in CD3+CD56+ and a decrease in B lymphocytes. Patients with an increased CD4/CD8 ratio have a better chance of responding to neoadjuvant chemotherapy.</description><identifier>ISSN: 0300-8916</identifier><identifier>EISSN: 2038-2529</identifier><identifier>DOI: 10.1177/030089160008600507</identifier><identifier>PMID: 11130570</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Antigens, CD - drug effects ; B-Lymphocyte Subsets - drug effects ; Breast Neoplasms - drug therapy ; Breast Neoplasms - immunology ; Breast Neoplasms - pathology ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - immunology ; Carcinoma, Ductal, Breast - pathology ; CD4-CD8 Ratio ; Chemotherapy, Adjuvant ; Disease Progression ; Female ; Humans ; Interleukin-2 - biosynthesis ; Killer Cells, Natural - drug effects ; Lymphocyte Count ; Lymphocyte Subsets - drug effects ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; T-Lymphocyte Subsets - drug effects</subject><ispartof>Tumori, 2000-09, Vol.86 (5), p.403-407</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-c817c1798f3973c222b3880e4ca373ba524a3227f53f922068671581c7d263503</citedby><cites>FETCH-LOGICAL-c299t-c817c1798f3973c222b3880e4ca373ba524a3227f53f922068671581c7d263503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11130570$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murta, E F</creatorcontrib><creatorcontrib>de Andrade, J M</creatorcontrib><creatorcontrib>Falcão, R P</creatorcontrib><creatorcontrib>Bighetti, S</creatorcontrib><title>Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy</title><title>Tumori</title><addtitle>Tumori</addtitle><description>There is an enhanced immune response in patients with breast cancer after the use of chemotherapy. The objective of this study was therefore to investigate alterations in the number of peripheral lymphocytes in patients with breast cancer after neoadjuvant chemotherapy (NC) and the relationship with prognosis. Thirty women were analyzed. Their UICC staging was IIb (only T3N0 included) and III (N3 not included). Sample analysis was performed using flow cytometry before the first cycle and 18 to 21 days after the last cycle of NC. The lymphocyte subsets studied were: T (CD3, CD4, CD8), B (CD19, CD23), natural killer (NK) (CD56, CD16), and interleukin-2 (CD25). CD3, CD56, CD8, and CD16 lymphocytes were analyzed with double marking. After x = 3.8 +/- 1.3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC), 16 patients showed a complete or partial response (group 1). After three cycles 14 showed no response or tumor progression (group 2). A control group of healthy women was used for pretreatment analysis. Before NC there was a significant increase in B lymphocytes and NK cells in comparison to the control group. After NC there was a significant percentage increase in CD3, CD4, CD8, CD25 and CD3+CD56+ cells and a decrease in CD19, CD23, CD56, CD16 and CD16+CD8+ cells. There was a significant fall in the absolute number of CD4, CD19, CD23, CD56, CD16 and CD16+CD8+ lymphocytes and an increase in CD3+CD56+ lymphocytes. Before NC the ratio CD4/CD8 in group 1 was 2.25 +/- 0.5 and in group 2 it was 1.79 +/- 0.5 (P &lt;0.05). Patients with advanced breast cancer showed increases in B and NK lymphocytes. Neoadjuvant chemotherapy (FEC) caused an increase in CD3+CD56+ and a decrease in B lymphocytes. Patients with an increased CD4/CD8 ratio have a better chance of responding to neoadjuvant chemotherapy.</description><subject>Adult</subject><subject>Antigens, CD - drug effects</subject><subject>B-Lymphocyte Subsets - drug effects</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - immunology</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>CD4-CD8 Ratio</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Interleukin-2 - biosynthesis</subject><subject>Killer Cells, Natural - drug effects</subject><subject>Lymphocyte Count</subject><subject>Lymphocyte Subsets - drug effects</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>T-Lymphocyte Subsets - drug effects</subject><issn>0300-8916</issn><issn>2038-2529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkEtPxCAUhYnROOPoH3BhWLmrwqUtsDQTX8kkbnTdUEptJ22pQDX999LMJC7c3Ad85wQOQteU3FHK-T1hhAhJcxJbLBnhJ2gNhIkEMpCnaL0AyUKs0IX3e0JSAnl-jlaUUkYyTtboczf3Y2P1HAz2UznacepUaO3gcTvgMY5mCB7_tKHBqvpWgzYVLp1RPmC9bG6R9W0I8TxYPBirqv0UwXjfmN6Gxjg1zpforFadN1fHvkEfT4_v25dk9_b8un3YJRqkDIkWlGvKpaiZ5EwDQMmEICbVinFWqgxSxQB4nbFaApBc5JxmgmpeQc4ywjbo9uA7Ovs1GR-KvvXadJ2KL5t8wSGVMRwWQTiA2lnvnamL0bW9cnNBSbHEW_yPN4puju7xz6b6kxzzZL-DW3Ws</recordid><startdate>20000901</startdate><enddate>20000901</enddate><creator>Murta, E F</creator><creator>de Andrade, J M</creator><creator>Falcão, R P</creator><creator>Bighetti, S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000901</creationdate><title>Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy</title><author>Murta, E F ; de Andrade, J M ; Falcão, R P ; Bighetti, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-c817c1798f3973c222b3880e4ca373ba524a3227f53f922068671581c7d263503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Antigens, CD - drug effects</topic><topic>B-Lymphocyte Subsets - drug effects</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - immunology</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>CD4-CD8 Ratio</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Interleukin-2 - biosynthesis</topic><topic>Killer Cells, Natural - drug effects</topic><topic>Lymphocyte Count</topic><topic>Lymphocyte Subsets - drug effects</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>T-Lymphocyte Subsets - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murta, E F</creatorcontrib><creatorcontrib>de Andrade, J M</creatorcontrib><creatorcontrib>Falcão, R P</creatorcontrib><creatorcontrib>Bighetti, S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Tumori</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murta, E F</au><au>de Andrade, J M</au><au>Falcão, R P</au><au>Bighetti, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy</atitle><jtitle>Tumori</jtitle><addtitle>Tumori</addtitle><date>2000-09-01</date><risdate>2000</risdate><volume>86</volume><issue>5</issue><spage>403</spage><epage>407</epage><pages>403-407</pages><issn>0300-8916</issn><eissn>2038-2529</eissn><abstract>There is an enhanced immune response in patients with breast cancer after the use of chemotherapy. The objective of this study was therefore to investigate alterations in the number of peripheral lymphocytes in patients with breast cancer after neoadjuvant chemotherapy (NC) and the relationship with prognosis. Thirty women were analyzed. Their UICC staging was IIb (only T3N0 included) and III (N3 not included). Sample analysis was performed using flow cytometry before the first cycle and 18 to 21 days after the last cycle of NC. The lymphocyte subsets studied were: T (CD3, CD4, CD8), B (CD19, CD23), natural killer (NK) (CD56, CD16), and interleukin-2 (CD25). CD3, CD56, CD8, and CD16 lymphocytes were analyzed with double marking. After x = 3.8 +/- 1.3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC), 16 patients showed a complete or partial response (group 1). After three cycles 14 showed no response or tumor progression (group 2). A control group of healthy women was used for pretreatment analysis. Before NC there was a significant increase in B lymphocytes and NK cells in comparison to the control group. After NC there was a significant percentage increase in CD3, CD4, CD8, CD25 and CD3+CD56+ cells and a decrease in CD19, CD23, CD56, CD16 and CD16+CD8+ cells. There was a significant fall in the absolute number of CD4, CD19, CD23, CD56, CD16 and CD16+CD8+ lymphocytes and an increase in CD3+CD56+ lymphocytes. Before NC the ratio CD4/CD8 in group 1 was 2.25 +/- 0.5 and in group 2 it was 1.79 +/- 0.5 (P &lt;0.05). Patients with advanced breast cancer showed increases in B and NK lymphocytes. Neoadjuvant chemotherapy (FEC) caused an increase in CD3+CD56+ and a decrease in B lymphocytes. Patients with an increased CD4/CD8 ratio have a better chance of responding to neoadjuvant chemotherapy.</abstract><cop>United States</cop><pmid>11130570</pmid><doi>10.1177/030089160008600507</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-8916
ispartof Tumori, 2000-09, Vol.86 (5), p.403-407
issn 0300-8916
2038-2529
language eng
recordid cdi_proquest_miscellaneous_72495293
source Access via SAGE; MEDLINE
subjects Adult
Antigens, CD - drug effects
B-Lymphocyte Subsets - drug effects
Breast Neoplasms - drug therapy
Breast Neoplasms - immunology
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - drug therapy
Carcinoma, Ductal, Breast - immunology
Carcinoma, Ductal, Breast - pathology
CD4-CD8 Ratio
Chemotherapy, Adjuvant
Disease Progression
Female
Humans
Interleukin-2 - biosynthesis
Killer Cells, Natural - drug effects
Lymphocyte Count
Lymphocyte Subsets - drug effects
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
T-Lymphocyte Subsets - drug effects
title Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A05%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lymphocyte%20subpopulations%20in%20patients%20with%20advanced%20breast%20cancer%20submitted%20to%20neoadjuvant%20chemotherapy&rft.jtitle=Tumori&rft.au=Murta,%20E%20F&rft.date=2000-09-01&rft.volume=86&rft.issue=5&rft.spage=403&rft.epage=407&rft.pages=403-407&rft.issn=0300-8916&rft.eissn=2038-2529&rft_id=info:doi/10.1177/030089160008600507&rft_dat=%3Cproquest_cross%3E72495293%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72495293&rft_id=info:pmid/11130570&rfr_iscdi=true